MAPT and tauopathy: Importantly, this assay has been optimized for 384-well compound screening (27) and, unlike most previously described cell-based assays of tau inclusion formation (29, 30, 31, 32), it utilizes the cell type (neurons) most affected in tauopathies without transgene overexpression of tau.